A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn s Disease

Brief description of study

The primary objective is to evaluate the efficacy of JNJ-active compunds as measured by the change in the Crohn’s Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn’s disease (SES-CD) from baseline at Week 12. This allows you the chance to receive one of the investigational treatments being researched for people with Crohn’s disease, faster.


Clinical Study Identifier: s17-00190
ClinicalTrials.gov Identifier: NCT04102111
Principal Investigator: Seymour Katz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.